Comparative Pharmacology
Head-to-head clinical analysis: AEROSPORIN versus OCUSULF 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSPORIN versus OCUSULF 10.
AEROSPORIN vs OCUSULF-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polymyxin B binds to the lipid A portion of bacterial lipopolysaccharides, disrupting the outer membrane permeability and causing bacterial cell death. It is primarily active against Gram-negative bacteria.
Sulfacetamide sodium is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and exerting bacteriostatic effects.
Polymyxin B sulfate: 1.5-2.5 mg/kg/day intravenously divided every 12 hours, or 25,000-30,000 units/kg/day intramuscularly divided every 12 hours. Ophthalmic: 1-2 drops in affected eye every 4 hours. Topical: Apply to affected area 3-4 times daily.
Instill 1 drop into the affected eye(s) every 4 hours while awake.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min), necessitating dose adjustment.
1.5–2.5 hours (terminal) in adults; prolonged to 3–5 hours in renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug via glomerular filtration. Approximately 60-70% of an intravenous dose is recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic